Literature DB >> 25319990

Retinal toxicity after intracameral use of a standard dose of cefuroxime during cataract surgery.

Céline Faure1, Daniel Perreira, Isabelle Audo.   

Abstract

PURPOSE: We report the clinical findings and retinal function of a patient who presented retinal toxicity signs after cefuroxime use for a phacoemulsification surgery.
METHODS: A 64-year-old man underwent a technically uneventful left eye cataract surgery. A standard intracameral dose of cefuroxime (0.1 mL of 10.0 mg/mL solution) was administered at the end of the surgery.
RESULTS: At review 2 days later, he complained about left eye visual loss. Fundus examination revealed a diffuse retinal pallor with small intraretinal cysts. Optical coherence tomography scans showed a large retinal serous detachment with a schisis-like appearance of the outer nuclear layer. A slight global retinal dysfunction was recorded on ISCEV full-field electroretinogram. Fast clinical recovery was observed. Optical coherence tomography scans were back to normal within less than a week. Two months later, full-field electroretinogram showed no longer abnormalities.
CONCLUSION: It is the first report to our knowledge of a case of retinal toxicity with a standard dose. Kinetics and studies about cefuroxime toxicity are reviewed and discussed.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25319990     DOI: 10.1007/s10633-014-9465-7

Source DB:  PubMed          Journal:  Doc Ophthalmol        ISSN: 0012-4486            Impact factor:   2.379


  26 in total

1.  ESCRS study of prophylaxis of postoperative endophthalmitis after cataract surgery: Preliminary report of principal results from a European multicenter study.

Authors:  Peter Barry; David V Seal; George Gettinby; Fiona Lees; Magnus Peterson; Crawford W Revie
Journal:  J Cataract Refract Surg       Date:  2006-03       Impact factor: 3.351

2.  Macular thickness after cataract surgery with intracameral cefuroxime.

Authors:  Mamta S Gupta; Hamish D R McKee; Manuel Saldaña; Owen G Stewart
Journal:  J Cataract Refract Surg       Date:  2005-06       Impact factor: 3.351

3.  ISCEV Standard for full-field clinical electroretinography (2008 update).

Authors:  M F Marmor; A B Fulton; G E Holder; Y Miyake; M Brigell; M Bach
Journal:  Doc Ophthalmol       Date:  2008-11-22       Impact factor: 2.379

4.  Cefuroxime dilution error.

Authors:  Yasar Sakarya; Rabia Sakarya
Journal:  Eur J Ophthalmol       Date:  2010 Mar-Apr       Impact factor: 2.597

Review 5.  Fingolimod-associated macular edema: incidence, detection, and management.

Authors:  Nieraj Jain; M Tariq Bhatti
Journal:  Neurology       Date:  2012-02-28       Impact factor: 9.910

6.  Physiological and toxicological effects of cefuroxime on the albino rabbit retina.

Authors:  Jonathan Shahar; Esther Zemel; Ido Perlman; Anat Loewenstein
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-02-21       Impact factor: 4.799

7.  Macular infarction after inadvertent intracameral cefuroxime.

Authors:  Farhan Qureshi; David Clark
Journal:  J Cataract Refract Surg       Date:  2011-06       Impact factor: 3.351

8.  Ocular toxicity after intracameral injection of very high doses of cefuroxime during cataract surgery.

Authors:  Marie-Noëlle Delyfer; Marie-Bénédicte Rougier; Sandy Leoni; Qiuhua Zhang; Francis Dalbon; Joseph Colin; Jean-François Korobelnik
Journal:  J Cataract Refract Surg       Date:  2011-02       Impact factor: 3.351

9.  Vancomycin levels after intravitreal injection. Effects of inflammation and surgery.

Authors:  H E Aguilar; T A Meredith; A el-Massry; A Shaarawy; M Kincaid; J Dick; D J Ritchie; R M Reichley; M K Neisman
Journal:  Retina       Date:  1995       Impact factor: 4.256

10.  Comparison of in vitro safety profiles of vancomycin and cefuroxime on human corneal endothelial cells for intracameral use.

Authors:  Efdal Yoeruek; Martin S Spitzer; Oguzhan Saygili; Olcay Tatar; Tilo Biedermann; Erdal Yoeruek; Karl U Bartz-Schmidt; Peter Szurman
Journal:  J Cataract Refract Surg       Date:  2008-12       Impact factor: 3.351

View more
  8 in total

1.  Acute macular edema and serous detachment on the first day after phacoemulsification surgery: A case report.

Authors:  Edyta Chlasta-Twardzik; Anna Nowińska; Edward Wylęgała
Journal:  Am J Ophthalmol Case Rep       Date:  2020-09-01

2.  Retinal toxicity secondary to subconjunctival cefuroxime following pars plana vitrectomy: A case report and literature review.

Authors:  Antony Raharja; James E Neffendorf; Tom H Williamson
Journal:  Am J Ophthalmol Case Rep       Date:  2022-05-02

3.  Intracameral cefuroxime in combined pars plana vitrectomy and phacoemulsification: a study of safety.

Authors:  Gianluca Besozzi; Attilio Di Salvatore; Daniele Cardillo; Alessandro Finzi; Joseph Sajish Pinackatt; Andrea Baldi; Alessandro Monfardini; Valeria Forioli; Rino Frisina; Barbara Parolini
Journal:  Clin Ophthalmol       Date:  2018-08-28

4.  High dose cefuroxime causing retinal toxicity in a patient undergoing trabeculectomy.

Authors:  Jae Yee Ku; Shiao Wei Wong; Laura R Steeples; Claire Delaney; Neil R A Parry; Cecilia Fenerty
Journal:  Am J Ophthalmol Case Rep       Date:  2022-02-02

5.  Macular edema with serous retinal detachment post-phacoemulsification followed by spectral domain optical coherence tomography: a report of two cases.

Authors:  Hui Xiao; Xing Liu; Xinxing Guo
Journal:  BMC Res Notes       Date:  2015-11-04

Review 6.  Post-cataract surgery endophthalmitis: Brief literature review.

Authors:  Hesam Hashemian; Reza Mirshahi; Mehdi Khodaparast; Mahmoud Jabbarvand
Journal:  J Curr Ophthalmol       Date:  2016-06-11

7.  Development of Retinal Infarct Due to Intracameral Cefuroxime Injection Following Complicated Cataract Surgery

Authors:  Sabahattin Sül; Aylin Karalezli
Journal:  Turk J Ophthalmol       Date:  2018-12-27

Review 8.  Postoperative Endophthalmitis and Toxic Anterior Segment Syndrome Prophylaxis: 2020 Update.

Authors:  Jesse D Sengillo; Ying Chen; Diley Perez Garcia; Stephen G Schwartz; Andrzej Grzybowski; Harry W Flynn
Journal:  Ann Transl Med       Date:  2020-11
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.